

Normothermic Machine Perfusion Market is Going to Booming Growth 2026-2033 | TransMedics Group Inc, OrganOx Limited

The global normothermic machine perfusion market is estimated to be valued at USD 2.05 Bn in 2026 and is expected to reach USD 6.57 Bn by 2033.

BURLINGAME, CA, UNITED STATES, May 7, 2026 /EINPresswire.com/ -- The Global [Normothermic Machine Perfusion Market](#) is estimated to be valued at USD 2.05 Bn in 2026 and is expected to reach USD 6.57 Bn by 2033, expanding at a compound annual growth rate (CAGR) of 18.11% from 2026 to 2033. The growing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and chronic kidney disease has significantly increased the global demand for organ transplants. These conditions often lead to organ failure, creating a critical need for effective organ preservation and evaluation methods to ensure optimal donor organ viability.



MARKET RESEARCH REPORTS BY 2026-2033

COHERENT MARKET INSIGHTS

- Market Sizing
- Regional Outlook
- Industry Analysis
- Competitive Analysis

Market Size (USD Billion)

Year	North America	APAC	Industry Sector 1	Industry Sector 2
2026	\$16B	\$24B	\$24B	\$24B
2027	\$18B	\$28B	\$28B	\$28B
2028	\$20B	\$32B	\$32B	\$32B
2029	\$22B	\$36B	\$36B	\$36B
2030	\$24B	\$40B	\$40B	\$40B
2031	\$26B	\$44B	\$44B	\$44B
2032	\$28B	\$48B	\$48B	\$48B
2033	\$30B	\$52B	\$52B	\$52B

CREDIBILITY AND CERTIFICATIONS

- ESOMAR²⁴ Individual
- Clutch 4.5 ★★★★★
- Top Market Research Agency
- ISO 9001:2015 CERTIFIED COMPANY

Normothermic Machine Perfusion Market

Get the Sample Copy of the Report at: <https://www.coherentmarketinsights.com/insight/request-sample/9141>

Key Takeaways

By application, organ preservation segment is slated to account for 44.5% of the global normothermic machine perfusion market share in 2026.

Based on organ type, kidney segment is expected to lead the market with a 32.4% share in 2026.

Hospitals and surgical centers are likely to remain the leading end-users of normothermic machine perfusion, with the target segment accounting for a market share of 34.6% by 2026.

North America is expected to dominate the global normothermic machine perfusion industry, accounting for a 41.4% share in 2026.

Asia Pacific, with 23.5% share in 2026, is poised to emerge as the fastest growing normothermic machine perfusion market during the forecast period.

Growing Demand for Organ Transplantation Fueling Market Growth

Coherent Market Insights' new normothermic machine perfusion market analysis outlines major factors driving industry growth. These include rising demand for organ transplantation, increasing demand for advanced organ preservation techniques, growing regulatory support, and technological advancements in normothermic machine perfusion systems.

The global need for organ transplants is increasing due to rising prevalence of end-stage organ failure, including renal, cardiac, and liver failure. This expanding patient pool is driving demand for effective organ preservation technologies such as normothermic machine perfusion, which can improve organ viability and utilization.

For example, The Lancet reports that chronic kidney disease (CKD) affects around 9%–14% of adults worldwide. The rising number of CKD cases and their progression to end-stage renal disease (ESRD) is expected to increase demand for kidney transplantation, which in turn supports growth of the normothermic machine perfusion market.

Furthermore, the Global Observatory on Donation and Transplant (GODT) states that over 95,479 kidney transplants are performed globally each year. This shows the growing need for advanced organ preservation solutions such as normothermic machine perfusion.

Purchase Now Up to 40% Discount on This Premium Report @
<https://www.coherentmarketinsights.com/offernew/buy-now/9141>

High Costs and Shortage of Donor Organs Limiting Market Growth

The global normothermic machine perfusion market outlook indicates robust future growth, owing to rising prevalence of organ failure, growing demand for organ transplants, and increasing need for advanced organ preservation technologies. However, limited availability of donor organs and high cost of advanced preservation technologies might slow down normothermic machine perfusion market growth to some extent during the forecast period.

Normothermic perfusion machines and related technologies are quite expensive. This could limit

their adoption in many smaller hospitals or transplant centers. In addition, the global shortage of transplantable organs naturally limits the total number of procedures where NMP can be used, which in turn restricts overall normothermic machine perfusion market demand.

Rising Need for Advanced Organ Preservation Techniques Creating Growth Opportunities

Normothermic perfusion maintains donor organs at near-body temperatures using oxygenated blood or perfusate. This approach helps improve organ viability, reduce ischemic injury, and support better transplant outcomes. These advantages of normothermic machine perfusion are making it an effective alternative to cold storage and other traditional organ preservation technologies, thereby creating growth opportunities for the market.

Emerging Normothermic Machine Perfusion Market Trends

The increasing use of marginal and donation after circulatory death (DCD) organs is expected to drive demand for normothermic machine perfusion (NMP) technologies during the forecast period. NMP systems improve preservation and viability assessment of higher-risk donor organs, expanding the usable donor pool as well as supporting market growth.

More medical professionals and transplant surgeons are recognizing the clinical advantages of NMP. This increasing awareness is leading to higher adoption rates in transplant centers worldwide, thereby fueling overall normothermic machine perfusion demand.

Healthcare infrastructure is improving in regions like Asia Pacific and Latin America, creating new opportunities for NMP adoption. Growing transplant programs and investment in advanced preservation technologies are helping the market expand in these emerging regions.

Growing research and innovation in organ preservation technologies are enhancing NMP system capabilities. New developments in sensors, perfusion solutions, and monitoring tools are making NMP more effective and reliable, which is boosting its adoption globally.

New technologies like real-time monitoring, AI analytics, and automated perfusion control are making NMP systems easier to use and more reliable. Improved perfusate solutions, portable designs, and biocompatible materials are also boosting clinical confidence and adoption worldwide. Companies are developing miniaturized and portable normothermic machine perfusion systems to expand usage in logistics and decentralized transplant workflows.

Request For Customization: <https://www.coherentmarketinsights.com/insight/request-customization/9141>

Analyst's View

"The global normothermic machine perfusion market is poised for robust growth, driven by the

rising demand for organ transplantation, increasing prevalence of end-stage organ failure, growing awareness of advanced organ preservation techniques, and ongoing technological innovations that improve graft viability and transplant outcomes,” said a senior CMI analyst.

Competitor Insights

Key companies in normothermic machine perfusion market report:

Organ Recovery Systems
TransMedics Group Inc.
XVIVO Perfusion AB
Getinge (Paragonix Technologies)
Bridge to Life Ltd
OrganOx Limited
Waters Medical Systems
Institut Georges Lopez SA
EBERS Medical Technology SL
Preservation Solutions Inc.
Shenzhen Lifotronic Technology Co Ltd
Terumo Corporation
Genus Medical Technologies LLC
LivaNova Plc
Medtronic plc

Key Developments

In August 2025, Terumo Corporation announced acquisition of OrganOx Limited. This marked Terumo’s strategic entry into the organ transplantation sector.

In November 2024, eGenesis and OrganOx announced a clinical co-development agreement to treat patients with acute liver failure. Under this agreement, OrganOx’s normothermic machine perfusion (NMP) technology will be used together with eGenesis’ human-compatible, genetically engineered pig livers to treat patients with liver failure.

In May 2024, OrganOx opened a state-of-the-art research, development, and production headquarters in Oxford, UK. OrganOx is known for its normothermic perfusion devices, like the metra[®], which keep organs at body temperature to help improve preservation before transplantation.

About Us:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has

excelled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Raj Shah

Coherent Market Insights Pvt. Ltd.

+1 252-477-1362

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/911055910>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.